放疗野内复发性子宫内膜癌与宫颈癌的免疫治疗反应评估
结果显示两组癌症中不同复发位置的完全缓解率和生存结局均无显著差异。
要点
- 子宫内膜癌野内复发者完全缓解率44.4%,野内外均有20.8%,野外25.6%,差异无统计学意义。
- 宫颈癌野内复发者完全缓解率16.7%,野内外均有24%,野外10%,差异无统计学意义。
- 复发位置相对于既往放疗野不影响免疫治疗的缓解率和生存结局。
核心结论
- 在复发性子宫内膜癌或宫颈癌中,免疫治疗反应和生存结局不因复发位置相对于既往放疗野不同而存在差异。
主要发现
- 子宫内膜癌中12%复发于放疗野内,32%野内外均有,55%野外;宫颈癌中分别为20%、44%和36%。
- 子宫内膜癌三组完全缓解率分别为44.4%、20.8%和25.6%(p=0.58),中位无进展生存期分别为86.5、9.7和6.8个月。
- 宫颈癌三组完全缓解率分别为16.7%、24%和10%(p=0.31),中位无进展生存期分别为12.2、4.6和3.4个月。
临床怎么用
- 对于既往放疗野内复发的子宫内膜癌或宫颈癌患者,免疫治疗可作为考虑选项,不必因复发位于放疗野内而排除免疫治疗。
局限性
- 回顾性单中心设计,样本量有限,仅行描述性和单因素分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Historical data suggest chemotherapy responses are poor in gynecologic cancer patients with recurrence in previously radiated fields, but the effectiveness of immunotherapy (IO) in this setting remains unclear. This study evaluated IO response and survival in patients with endometrial (EC) and cervical cancer (CC) with recurrence within or outside the radiated field. METHODS: A retrospective, single-institution cohort study was conducted in EC and CC patients treated with IO between 2017 and 2023. Patients were categorized by recurrence site: (1) within the radiated field, (2) both in and out of the radiated field, and (3) outside the radiated field. Descriptive and univariate analyses were performed. Progression-free survival (PFS) was defined from IO initiation to progression or death, and overall survival (OS) from diagnosis to death. Kaplan-Meier methods assessed survival. RESULTS: Seventy-four patients with EC and 59 with CC were included. In EC, 12% recurred within the radiated field, 32% both in and out, and 55% outside. In CC, 20% recurred within the radiated field, 44% both in and out, and 36% outside. Complete response rates (CRR) and survival outcomes were similar across groups. For EC, CRRs were 44.4%, 20.8%, and 25.6% (p = 0.58) with median PFS of 86.5, 9.7, and 6.8 months, respectively. For CC, CRRs were 16.7%, 24%, and 10% (p = 0.31) with median PFS of 12.2, 4.6, and 3.4 months. CONCLUSIONS: IO response and survival outcomes did not differ by recurrence location relative to prior radiation fields in recurrent EC or CC.
引用
- Chalif J, Morton M, Gonzalez A, et al. Evaluation of immunotherapy response in the radiated field in patients with recurrent endometrial and cervical cancer. Gynecol Oncol. 2026. PMID: 41930528. doi:10.1016/j.ygyno.2026.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。